7.088USD-0.03%Mkt Cap: —P/E: —1d ago
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting C…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value-40.62M $
Revenue (TTM)4.62M $
Gross Profit-22.57M $
Net Income (TTM)-30.91M $
Revenue/Share1.141 USD
Last Price7.088 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees34
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.81
EV/Revenue-8.80
P/S—
P/B-0.95
EPS (TTM)-3.04
EPS (Forward)—
52W Range
6.81076% of range7.175
52W High7.175 USD
52W Low6.810 USD
Profitability
Gross Margin0.00%
Oper. Margin1191.52%
EBITDA Margin0.00%
Profit Margin3968.63%
ROE—
ROA-22.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.05M $
CapEx (TTM)—
FCF Margin1171.46%
FCF Yield—
Net Debt-91.32M $
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity—
Current Ratio2.69
Quick Ratio2.54
Book Value/Sh-7.4450 USD
Cash/Share22.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.04:1
Split DateJun 17, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.84.98M
Float3.56M
Insiders2.02%
Institutions24.68%
Technical
SMA 501.582 (+348.0%)
SMA 2002.791 (+154.0%)
Beta1.04
S&P 52W Chg18.16%
Avg Vol (30d)1.05K
Avg Vol (10d)27.00K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—